BioNotebook: Post-Thanksgiving blues for Exelixis, Pozen; Burrill notes tripling of M&A deals in 2014
This article was originally published in Scrip
Executive Summary
Public companies often try to sneak their bad news into the evening hours following stock market closing time on the day before Thanksgiving – or on the eve of any major holiday, really – but Pozen and Exelixis waited until everyone came back to work from their turkey dinners and meals of endless leftovers to announce the loss of a major partner and a bad set of Phase III results.
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.